Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.

ABSTRACT:

Aims

Defining responders to glucose lowering therapy can be important for both clinical care and for the development of a stratified approach to diabetes management. Response is commonly defined by either HbA1c change after treatment or whether a target HbA1c is achieved. We aimed to determine the extent to which the individuals identified as responders and non-responders to glucose lowering therapy, and their characteristics, depend on the response definition chosen.

Methods

We prospectively studied 230 participants commencing GLP-1 agonist therapy. We assessed participant characteristics at baseline and repeated HbA1c after 3 months treatment. We defined responders (best quartile of response) based on HbA1c change or HbA1c achieved. We assessed the extent to which these me

SUBMITTER: Jones AG 

PROVIDER: S-EPMC4207765 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature